The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

On Wednesday, Bernstein analysts increased their price target for Cigna Corporation (NYSE: CI) shares from $323.00 to $373.00, while maintaining a Market Perform rating.The healthcare giant, with ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Specialty benefit vendors have made big promises about lower costs and healthier workers. Employers are now demanding ...

Health insurance company Cigna (NYSE:CI ... The company cited persistent medical cost trends, evolving drug pricing dynamics, and regulatory changes (e.g., state-level PBM legislation) as key ...

Healthcare has been running neck and neck with energy and consumer discretionary for the worst sector of 2025.

Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will make the medicines available to more patients.

After Donald Trump signed an executive order slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies ...

U.S. prices for new drugs more than doubled last year compared to 2021, as companies developed more therapies for rare ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.